Impact of Combined Chronic Obstructive Pulmonary Disease Status and Systemic Inflammation on Outcome of Advanced NSCLC: Multicenter Retrospective Cohort Study

被引：4

作者：

Lim, Jeong Uk ^{[1
]}

Kang, Hye Seon ^{[2
]}

Yeo, Chang Dong ^{[3
]}

Kim, Ju Sang ^{[4
]}

Park, Chan Kwon ^{[1
]}

Kim, Yong Hyun ^{[2
]}

Kim, Jin Woo ^{[5
]}

Kim, Seung Joon ^{[6
,7
]}

Lee, Sang Haak ^{[3
,7
]}

机构：

[1] Catholic Univ Korea, Coll Med, Yeouido St Marys Hosp, Div Pulm Crit Care & Allergy,Dept Internal Med, Seoul, South Korea

[2] Catholic Univ Korea, Coll Med, Bucheon St Marys Hosp, Div Pulm Crit Care & Allergy,Dept Internal Med, Bucheon, South Korea

[3] Catholic Univ Korea, Coll Med, Eunpyeong St Marys Hosp, Div Pulm Crit Care & Sleep Med,Dept Internal Med, Seoul, South Korea

[4] Catholic Univ Korea, Coll Med, Incheon St Marys Hosp, Div Pulm Crit Care & Sleep Allergy,Dept Internal, Seoul, South Korea

[5] Catholic Univ Korea, Coll Med, Uijeongbu St Marys Hosp, Div Pulm Crit Care & Sleep Med,Dept Internal Med, Seoul, South Korea

[6] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Div Pulm Crit Care & Allergy,Dept Internal Med, Seoul, South Korea

[7] Catholic Univ Korea, Coll Med, Canc Res Inst, Seoul, South Korea

来源：

INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2020年 / 15卷

关键词：

chronic obstructive pulmonary disease; non-small cell lung cancer; survival; platelet; lymphocyte; inflammation; biomarker; PLATELET-LYMPHOCYTE RATIO; LUNG-CANCER PATIENTS; PROGNOSTIC ROLE; COPD; SURVIVAL; EMPHYSEMA; METAANALYSIS; PREVALENCE; MORTALITY; RISK;

D O I：

10.2147/COPD.S274354

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Background: In patients with non-small cell lung cancer (NSCLC), both chronic obstructive pulmonary disease (COPD) and systemic inflammatory biomarkers, such as neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR), have significant association with prognosis. NLR and PLR also predict mortality in patients with COPD alone. A combination of the two parameters may be helpful in a more individualized approach for predicting prognosis in NSCLC. Methods: Medical records of patients with stage IIIB and IV NSCLC from January 2012 to January 2018 in seven university hospitals were reviewed. Patients were categorized into four subgroups based on pulmonary function test results and cutoffs for NLR or PLR. Results: A total of 277 patients were evaluated and categorized into non-COPD and COPD groups; 194 patients were in the non-COPD group and 83 patients were in the COPD group. The non-COPD group showed significantly longer overall survival (OS) compared with the COPD group (P = 0.019). Median survival was significantly different between high/low PLR groups (P < 0.001), between high/low NLR groups (P = 0.001), and between high/low c-reactive protein (CRP) groups (P < 0.001). PLR, NLR and CRP showed significant correlations with each other. PLR showed a significant negative linear correlation with FVC (absolute) (r = -0.149, P = 0.015), FVC (%) (r = -0.192, P = 0.002), DLCO (absolute) (r = -0.271, P < 0.001), DLCO (%) (r = -0.139, P= 0.032), and NLR (r = 0.718, P < 0.001). In the multivariate analysis, the high PLR, COPD sub-group showed significantly higher risk for mortality (HR 2.066 (1.175-3.633), P = 0.012) compared with the low-PLR non-COPD group. However, COPD-NLR subtype was not an independent predictor for OS. Conclusion: A combination of COPD status and PLR may be a cost-effective and readily available prognostic marker in patients with advanced NSCLC.

引用

页码：3323 / 3334

页数：12

共 43 条

[1]

[Anonymous], 2019, MEDICINE, DOI DOI 10.1097/MD.0000000000014837

[2] Inflammation and cancer: back to Virchow? [J].